Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-CF20
- Development stage
- Preclinical
- Lead developer
- GlycosBio
- Administration
- Oral
01
Overview
GB-CF20 (also known as GB-AOS-1 or EMO-ONS) is an investigational, ready-to-drink enzyme-modified oil oral nutritional supplement (EMO-ONS) developed by GlycosBio. It is designed using the company's proprietary Activated Oil System platform to provide highly bioavailable nutritional lipids for patients with cystic fibrosis who suffer from exocrine pancreatic insufficiency (EPI). GB-CF20 is formulated to bypass the need for pancreatic enzyme replacement therapy (PERT) by delivering pre-digested or easily absorbable lipids, essential fatty acids, amino acids, vitamins, and minerals, thereby addressing malnutrition without the gastrointestinal side effects associated with PERT.
- Other names
- EMO-ONSenzyme-modified oil oral nutritional supplement
Beyond the preview
Go deeper on GB-CF20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-CF20.